Zimmer Biomet (NYSE:ZBH) received a $113.00 target price from research analysts at Barclays in a research report issued on Tuesday, February 5th. The firm presently has a “sell” rating on the medical equipment provider’s stock. Barclays‘s target price would suggest a potential downside of 9.90% from the stock’s current price.
Several other brokerages have also weighed in on ZBH. Credit Suisse Group assumed coverage on Zimmer Biomet in a research report on Monday, December 17th. They issued an “underperform” rating and a $102.00 target price on the stock. Citigroup raised Zimmer Biomet from a “neutral” rating to a “buy” rating and increased their target price for the stock from $122.00 to $127.00 in a report on Wednesday, January 2nd. JPMorgan Chase & Co. cut Zimmer Biomet from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $140.00 to $118.00 in a report on Wednesday, December 19th. Jefferies Financial Group decreased their price objective on Zimmer Biomet from $145.00 to $140.00 and set a “buy” rating on the stock in a research report on Monday, October 29th. Finally, Stifel Nicolaus reduced their price target on Zimmer Biomet from $150.00 to $135.00 and set a “buy” rating on the stock in a research report on Tuesday, January 22nd. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $127.52.
ZBH stock traded up $1.29 during midday trading on Tuesday, hitting $125.41. 1,254,150 shares of the company’s stock were exchanged, compared to its average volume of 1,311,796. Zimmer Biomet has a 12-month low of $96.99 and a 12-month high of $134.55. The company has a quick ratio of 0.91, a current ratio of 1.85 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $25.38 billion, a PE ratio of 16.41, a P/E/G ratio of 2.23 and a beta of 1.16.
Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Friday, February 1st. The medical equipment provider reported $2.18 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $2.18. The company had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a positive return on equity of 13.17% and a negative net margin of 4.78%. The firm’s quarterly revenue was up .1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.10 EPS. As a group, sell-side analysts anticipate that Zimmer Biomet will post 7.82 EPS for the current year.
In related news, Director Betsy J. Bernard acquired 4,250 shares of the stock in a transaction on Wednesday, February 6th. The stock was acquired at an average cost of $117.41 per share, for a total transaction of $498,992.50. Following the completion of the acquisition, the director now directly owns 2,000 shares of the company’s stock, valued at approximately $234,820. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Arthur J. Higgins bought 500 shares of the stock in a transaction dated Friday, February 15th. The shares were acquired at an average price of $123.28 per share, with a total value of $61,640.00. Following the completion of the acquisition, the director now directly owns 2,400 shares of the company’s stock, valued at approximately $295,872. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 10,935 shares of company stock valued at $1,307,368. 0.71% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of ZBH. JPMorgan Chase & Co. grew its position in Zimmer Biomet by 9.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,595,444 shares of the medical equipment provider’s stock worth $1,524,453,000 after purchasing an additional 1,033,717 shares during the period. OppenheimerFunds Inc. boosted its stake in shares of Zimmer Biomet by 26.9% during the 3rd quarter. OppenheimerFunds Inc. now owns 2,477,866 shares of the medical equipment provider’s stock worth $325,765,000 after acquiring an additional 524,904 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Zimmer Biomet by 3.2% during the 3rd quarter. BlackRock Inc. now owns 15,812,529 shares of the medical equipment provider’s stock worth $2,078,872,000 after acquiring an additional 485,479 shares during the last quarter. Boston Partners boosted its stake in shares of Zimmer Biomet by 74.1% during the 4th quarter. Boston Partners now owns 1,083,978 shares of the medical equipment provider’s stock worth $112,430,000 after acquiring an additional 461,269 shares during the last quarter. Finally, Primecap Management Co. CA boosted its stake in shares of Zimmer Biomet by 33.3% during the 3rd quarter. Primecap Management Co. CA now owns 1,713,930 shares of the medical equipment provider’s stock worth $225,330,000 after acquiring an additional 428,311 shares during the last quarter. 88.65% of the stock is owned by institutional investors and hedge funds.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Featured Story: What is the float in trading stocks?
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.